RESTORING YOUR IMMUNE BALANCE

ON DEMAND CYTOKINE

Systemically Delivered / Locally Activated

ODCs are conditionally activated cytokine therapies

ODCs are engineered for optimal retention and targeted activation at the disease site

ODCs safely trigger cancer-fighting immune cells

Our Team

Phillip Kim PhD, MBA
CEO, Chairman of the Board

Emma Langley, PhD
COO, VP Research & Development

Hsieng Lu, PhD
Chief Development Advisor

Maria Ramirez, PhD
Head, Clinical Development

Boehringer Ingelheim Signs Option to Acquire Trutino Biosciences
Boehringer Ingelheim signed an option to acquire Trutino Biosciences Inc., a San Diego-based biotech company. Led by Phillip Kim, Ph.D., MBA, Founder and […]

Continue reading
713 Novel protease activatable linker with tumor targeting motifs enhances the retention of cytokine prodrug and active cytokine at disease site and demonstrates improved efficacy in preclinical model
Abstract Background An emerging class of new protease-activatable prodrugs designed to enhance on-target activity and reduce off-target toxicity are being actively developed. Cytokines […]

Continue reading
Abstract 1745: On demand cytokine, a novel cytokine prodrug, demonstrates robust single agent efficacy without systemic toxicity in syngeneic tumor models
Abstract Recombinant IL-2 (aldesleukin) is a potent T cell proliferation and differentiation factor and is an approved immunotherapy for advanced melanoma and renal […]

Continue reading